Five things for pharma marketers to know: Monday, July 24, 2017

Share this content:


1. Samsung Bioepis began selling rheumatoid arthritis drug Renflexis, a biosimilar of Johnson & Johnson's Remicade, in the U.S. The FDA approved Renflexis in April, making it the second biosimilar version of Remicade in the U.S. (Reuters)

2. The World Health Organization sanctioned the use of a generic version of Gilead Sciences' hepatitis C drug Sovaldi in an effort to widen access to lower-cost alternatives in some countries. (Stat)

3. More than 50% of people infected with HIV are now taking HIV/AIDs drugs to treat the virus, which is expected to curb the number of AIDS-related deaths to about half of what it was in 2005, according to a new report from the United Nations. In 2016, 19.5 million people with HIV were taking these drugs. (ABC News)

4. Drugmakers and universities are rushing to develop gene therapies for cancers such as breast, prostate, and lung, as the FDA is expected to approve gene therapy in the next few months. (NYT)

5. British drugstore chain Boots apologized for its response to a campaign to lower the price of the morning-after pill Levonelle and said it will look for cheaper alternatives. Advocates had argued that the drug is cheaper in other European countries. (Reuters)

Share this content:
Scroll down to see the next article